Rigor Reviewed

Rigor-Reviewed Manuscript

Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.

Name: Αlpha¹ Rigor Record — Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.
Item: Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.
Rating: 96
Author: Αlpha¹

Liu Y, Chen Y, Ma J, Lin J, Liu C, Li X, Xu Y, Kuang H, Shi L, Xue Y, Feng B, Zhu D, Wang G, Yang J, Xiao X, Yu X, Zhou J, Bao Y, Su Q, Lyu M, Li X, Zhang H, Li X

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 1 high issue for “Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 52 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported randomised controlled trial with rigorous design, clear reporting of methods and results, and appropriate ethical approvals. The main weakness is the vague data availability statement, which lacks a concrete access mechanism, and minor copyedit issues.

Both reviewers independently scored all eight dimensions and agreed on all statuses; no divergence was present. The statistics verification component checked only 2 tests (those with test statistics or effect estimates with CIs) and found them consistent; other reported statistics were not machine-verified. The citation check found no retracted or unresolved references.

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 1 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

Prior research is cited (DiRECT trial, bariatric surgery, SGLT-2 inhibitor mechanisms) with strengths and limitations acknowledged (e.g., very low energy diet challenge, surgery risks). The rationale logically connects energy deficit from dapagliflozin plus calorie restriction to remission. Limitations of prior approaches are addressed by proposing a more practicable regimen.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The introduction establishes a clear scientific premise, citing prior work (DiRECT, bariatric surgery, SGLT-2 inhibitors) and a logical hypothesis linking energy deficit to diabetes remission.

Evidence

paraphrase[Introduction, paragraph 1]

“In the DiRECT trial, participants who had had diabetes for up to six years underwent an intensive dietary intervention. Diabetes remission ... was achieved in 46% of the intervention group, with a mean body weight reduction of 10%. However, the strategy of a very low energy diet in routine care settings remains a challenge.”

direct quote[Introduction, paragraph 2]

“Thus, we hypothesised that dapagliflozin plus calorie restriction could achieve greater energy deficit and greater reduction of hyperglycaemia than calorie restriction alone and could lead to remission of diabetes in a generally acceptable way.”